What is Global Biosimilars Market?
The global biosimilars market is a rapidly evolving segment within the pharmaceutical industry, focusing on the development and commercialization of biosimilars. Biosimilars are essentially biologic medical products that are highly similar to already approved reference products, with no clinically meaningful differences in terms of safety, purity, and potency. These products are derived from living organisms and are used to treat a variety of diseases, including cancer, autoimmune disorders, and chronic diseases. The market for biosimilars is driven by the increasing demand for cost-effective alternatives to expensive biologic drugs, as well as the expiration of patents for many biologic drugs, which opens the door for biosimilar competition. Additionally, advancements in biotechnology and regulatory support from agencies like the FDA and EMA have facilitated the growth of this market. The global biosimilars market is characterized by intense competition among key players, ongoing research and development activities, and strategic collaborations to enhance product portfolios and expand market reach. As healthcare systems worldwide strive to reduce costs while maintaining high-quality care, biosimilars offer a promising solution to meet these objectives.
Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon), Recombinant Glycosylated Proteins in the Global Biosimilars Market:
Recombinant non-glycosylated proteins and recombinant glycosylated proteins are two major categories within the global biosimilars market, each playing a crucial role in the treatment of various medical conditions. Recombinant non-glycosylated proteins include insulin, recombinant human growth hormone (rHGH), and interferon. Insulin biosimilars are used to manage diabetes by regulating blood sugar levels, offering a more affordable option for patients compared to branded insulin products. The development of insulin biosimilars has been driven by the increasing prevalence of diabetes worldwide and the need for cost-effective treatment options. Recombinant human growth hormone (rHGH) biosimilars are used to treat growth hormone deficiencies in children and adults, as well as other conditions such as Turner syndrome and chronic kidney disease. These biosimilars provide a more accessible treatment option for patients who require long-term therapy. Interferon biosimilars are used in the treatment of viral infections, such as hepatitis C, and certain types of cancer, including melanoma and leukemia. They work by enhancing the immune system's ability to fight off infections and inhibit the growth of cancer cells. The development of interferon biosimilars has been driven by the need for more affordable treatment options for these serious conditions. On the other hand, recombinant glycosylated proteins include monoclonal antibodies and erythropoietin. Monoclonal antibody biosimilars are used in the treatment of various cancers, autoimmune diseases, and inflammatory conditions. They work by targeting specific proteins on the surface of cancer cells or immune cells, thereby inhibiting their growth and activity. The development of monoclonal antibody biosimilars has been fueled by the increasing demand for targeted therapies and the high cost of branded monoclonal antibody drugs. Erythropoietin biosimilars are used to treat anemia associated with chronic kidney disease, cancer, and other conditions. They stimulate the production of red blood cells, helping to alleviate the symptoms of anemia and improve patients' quality of life. The development of erythropoietin biosimilars has been driven by the need for more affordable treatment options for patients with anemia. Both recombinant non-glycosylated and glycosylated protein biosimilars have significantly contributed to the growth of the global biosimilars market. The increasing prevalence of chronic diseases, the rising demand for cost-effective treatment options, and the expiration of patents for many biologic drugs have all played a role in driving the development and commercialization of these biosimilars. Additionally, advancements in biotechnology and regulatory support from agencies like the FDA and EMA have facilitated the growth of this market. As the global biosimilars market continues to expand, it is expected to play an increasingly important role in the treatment of various medical conditions, offering patients more affordable and accessible treatment options.
Oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic and Autoimmune Disorders, Others in the Global Biosimilars Market:
The global biosimilars market has found significant applications in various therapeutic areas, including oncology, blood disorders, growth hormonal deficiency, chronic and autoimmune disorders, and others. In oncology, biosimilars are used to treat various types of cancer, including breast cancer, colorectal cancer, and non-Hodgkin's lymphoma. Monoclonal antibody biosimilars, such as trastuzumab and rituximab, are used to target specific proteins on the surface of cancer cells, inhibiting their growth and activity. These biosimilars offer a more affordable treatment option for cancer patients, helping to reduce the financial burden associated with cancer care. In the area of blood disorders, biosimilars are used to treat conditions such as anemia and hemophilia. Erythropoietin biosimilars are used to stimulate the production of red blood cells in patients with anemia, improving their quality of life and reducing the need for blood transfusions. Factor VIII biosimilars are used to treat hemophilia A, a genetic disorder that affects the blood's ability to clot. These biosimilars provide a more cost-effective treatment option for patients with blood disorders, helping to improve their overall health outcomes. In the treatment of growth hormonal deficiency, recombinant human growth hormone (rHGH) biosimilars are used to promote growth in children and adults with growth hormone deficiencies. These biosimilars offer a more accessible treatment option for patients who require long-term therapy, helping to improve their growth and development. In the area of chronic and autoimmune disorders, biosimilars are used to treat conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Tumor necrosis factor (TNF) inhibitor biosimilars, such as infliximab and adalimumab, are used to reduce inflammation and slow the progression of these diseases. These biosimilars offer a more affordable treatment option for patients with chronic and autoimmune disorders, helping to improve their quality of life and reduce the burden of disease. In addition to these therapeutic areas, biosimilars are also used in the treatment of other conditions, such as viral infections and osteoporosis. Interferon biosimilars are used to treat viral infections, such as hepatitis C, by enhancing the immune system's ability to fight off infections. Parathyroid hormone biosimilars are used to treat osteoporosis, a condition characterized by weak and brittle bones, by stimulating bone formation and increasing bone density. The global biosimilars market has significantly expanded the range of treatment options available to patients across various therapeutic areas, offering more affordable and accessible alternatives to branded biologic drugs. As the market continues to grow, it is expected to play an increasingly important role in the treatment of various medical conditions, helping to improve patient outcomes and reduce healthcare costs.
Global Biosimilars Market Outlook:
In 2024, the global biosimilars market was valued at approximately $8,086 million. By 2031, it is anticipated to grow to a revised size of around $25,370 million, reflecting a compound annual growth rate (CAGR) of 18.0% over the forecast period. This rapid growth is indicative of the increasing demand for biosimilars as cost-effective alternatives to traditional biologic drugs. In contrast, the global pharmaceutical market was valued at $1,475 billion in 2022, with a projected CAGR of 5% over the next six years. This comparison highlights the significantly faster growth rate of the biosimilars market compared to the broader pharmaceutical industry. Meanwhile, the chemical drug market, a subset of the pharmaceutical industry, was estimated to grow from $1,005 billion in 2018 to $1,094 billion in 2022. This growth trajectory underscores the expanding role of biosimilars within the pharmaceutical landscape, driven by factors such as patent expirations, increasing prevalence of chronic diseases, and the need for more affordable treatment options. As the biosimilars market continues to evolve, it is expected to play a crucial role in shaping the future of healthcare by providing patients with access to high-quality, cost-effective therapies.
| Report Metric | Details |
| Report Name | Biosimilars Market |
| Accounted market size in year | US$ 8086 million |
| Forecasted market size in 2031 | US$ 25370 million |
| CAGR | 18.0% |
| Base Year | year |
| Forecasted years | 2025 - 2031 |
| Segment by Type |
|
| Segment by Application |
|
| Consumption by Region |
|
| By Company | Pfizer, Novartis, Biocon, Biogen, Fresenius Kabi AG, Boehringer Ingelheim, Merck KgaA, Mylan, Eli Lilly, Teva Pharmaceutical, Dr. Reddy's Laboratories, Amgen, Celltrion, Samsung Biologics, Roche, Probiomed, Apotex, Chong Kun Dang, JCR Pharmaceuticals, Gan & Lee Pharmaceuticals, Gedeon Richter, Biocad, Coherus Bioscience, Stada Arzneimittel AG |
| Forecast units | USD million in value |
| Report coverage | Revenue and volume forecast, company share, competitive landscape, growth factors and trends |
